Products from BPS Bioscience require a minimum order value above 400€
Applications: This kit is useful for screening for inhibitors of CTLA4 binding to B7-2.
Background: B7-2 (CD86) signaling through CTLA4 (CD152) has been shown to inhibit T- cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host's immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer.
Description: The CTLA4:B7-2[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2-biotin interaction. The key to this kit is the high sensitivity of detection of CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, CTLA4 is coated on a 96-well plate. Next, B7-2-biotin is incubated with CTLA4 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.
Storage Stability: One year from date of receipt when stored as directed.
Supplied As: This kit comes in a convenient 96-well format, with CTLA4 (CD152), purified biotin-labeled B7-2 (CD86), streptavidin-labeled HRP, and assay buffer for 100 binding reactions.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Ohtani, H., et al., Lab Invest. 1997; 77(3): 231-241.
2. Robert, C., et al., N. Engl. J. Med. 2011; 364: 2517-2526.
English
Deutsch
